Skip to search formSkip to main contentSkip to account menu

MDX-060

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

iratumumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.
Background: MDX-060 is a fully human anti-CD30 IgG1k monoclonal antibody that induces Fc-receptor mediated killing of CD30… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)